Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for DRD2    
Back Search Methods Disclaimer Credits
 Gene: DRD2  (D2R; D2DR)  Entrez Gene    View on PDGene
 Protein: dopamine receptor D2  (seven transmembrane helix receptor)  ProteinLink
 Chromosome: 11   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 21 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Asherson, 1994
UK CL  1  (detail)  112
(-)
IIIR--64
(-)
-Negative
Bertolino, 2008
Italy CL  3  (detail)  196
(25%)
IV-33.5 + 12.8
(-)
249
(61%)
36.6 + 11.5
(-)
Positive
Betcheva, 2009
Bulgaria (I) CL  4  (detail)  185
(-)
IV--184
(-)
-Positive
Betcheva, 2009
Bulgaria (II) CL  2  (detail)  70
(-)
IV--372
(-)
-Positive
Breen, 1999
UK CL  1  (detail)  439
(-)
M--437
(-)
-Positive
Campion, 1994
France CL  1  (detail)  80
(-)
IIIR--80
(-)
-Negative
Comings, 1991
USA CL  1  (detail)  87
(-)
III--314
(-)
-Negative
Crawford, 1996
USA CL  1  (detail)  84
(-)
IIIR--81
(-)
-Negative
Dollfus, 1996
France CL  1  (detail)  62
(-)
M--161
(-)
-Negative
Dubertret, 2001
Overlaps with
Dubertret, 2010
CL  2  (detail)  50
(26%)
IV20.6 + 3.1
(-)
-50
(22%)
-n.a.
Dubertret, 2004
Overlaps with
Dubertret, 2010
CL  6  (detail)  103
(21%)
IV20.7 + 8
(-)
-83
(19%)
-n.a.
Dubertret, 2010
France CL  8  (detail)  252
(40%)
IV27.5
(-)
40.4
(-)
142
(54%)
73.6 + 8.3
(-)
Positive
Hall, 2007
Overlaps with
Jonsson, 2003
CL  1  (detail)  103
(38%)
M-42.4 + 11.5
(-)
89
(33%)
39.2 + 11.5
(-)
n.a.
Hanninen, 2006
Finland CL  1  (detail)  188
(45%)
IV27 + 8.9
(-)
43.1 + 12
(18-76)
384
(46%)
44.4 + 11.2
(19-65)
Positive
Hoenicka, 2006
Spain CL  1  (detail)  131
(42%)
IV--364
(-)
-Positive
Hoogendoorn, 2005
Netherlands CL  2  (detail)  208
(-)
IV--288
(-)
-Negative
Jonsson, 1996
Sweden CL  1  (detail)  118
(36%)
IIIR-45.8
(20-90)
78
(42%)
38.7
(29-56)
Negative
Jonsson, 1999
Sweden CL  1  (detail)  129
(36%)
IIIR-44.6 + 17.3
(-)
179
(52%)
45.3 + 15.9
(-)
Positive
Jonsson, 2003
Sweden CL  1  (detail)  173
(37%)
M-44 + 15.6
(-)
236
(37%)
39.8 + 10.3
(-)
Positive
Kampman, 2003
Finland CL  1  (detail)  93
(-)
IV--94
(-)
-Negative
Lafuente, 2008
Spain CL  3  (detail)  243
(46%)
IV-34 + 13
(-)
291
(62%)
61.7 + 11
(-)
Positive
Laurent, 1994
France CL  1  (detail)  113
(30%)
IIIR-42 + 0.6
(-)
184
(40%)
49 + 0.5
(-)
Negative
Lawford, 2005
Australia CL  1  (detail)  153
(13%)
IV-36.2 + 12.3
(18-65)
148
(29%)
36.8 + 12.8
(-)
Positive
Li, 1998
UK CL  1  (detail)  151
(56%)
M-29.4 + 10.9
(15-65)
145
(158%)
-Negative
Mas, 2009
Spain CL  13  (detail)  159
(-)
IV--373
(54%)
51.9 + 19
(-)
Negative
Meda, 2009
USA CL  2  (detail)  31
(-)
IV--35
(-)
-Negative
Monakhov, 2008
Russia CL  3  (detail)  311
(48%)
IV25.4 + 8.9
(-)
35.3 + 12.5
(-)
364
(62%)
31.7 + 12.7
(-)
Positive
Nothen, 1993
Germany CL  1  (detail)  60
(33%)
IIIR25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
Negative
Nothen, 1994
Germany CL  1  (detail)  179
(-)
III--138
(-)
-Negative
Parsons, 2007
Spain CL  2  (detail)  119
(34%)
IV-41.2 + 13.9
(-)
165
(51%)
26.8 + 5.4
(-)
Positive
Saiz, 2009
Spain CL  1  (detail)  288
(40%)
IV-36.3 + 12.4
(-)
421
(49%)
40.6 + 11.3
(-)
Positive
Sanders, 1993
USA CL  1  (detail)  55
(9%)
IIIR26 + 8
(13-56)
44 + 14
(21-71)
51
(6%)
60 + 10
(37-78)
Negative
Sanders, 2008
USA, Australia CL  31  (detail)  1870
(31%)
IV--2002
(53%)
-Negative
Sasaki, 1996
USA, Canada, Italy CL  1  (detail)  273
(33%)
IIIR-32 + 9
(-)
255
(50%)
-Negative
Serretti, 2000
Italy CL  1  (detail)  366
(-)
IV--267
(52%)
46.6 + 15.9
(-)
Negative
Shaikh, 1994
UK CL  1  (detail)  140
(-)
III--100
(-)
-Positive
Sobell, 1994
USA CL  1  (detail)  338
(-)
III--1914
(-)
-Negative
Spurlock, 1998
UK CL  1  (detail)  97
(-)
IIIR--106
(-)
-Negative
Spurlock, 1998
Italy CL  1  (detail)  103
(-)
IIIR--96
(-)
-Negative
Spurlock, 1998
Ireland CL  1  (detail)  34
(-)
IIIR--89
(-)
-Negative
Spurlock, 1998
Austria CL  1  (detail)  72
(-)
IIIR--57
(-)
-Negative
Stober, 1998
Germany CL  1  (detail)  260
(40%)
1026.9 + 9.4
(-)
-290
(45%)
29.3 + 9.7
(-)
Negative
Talkowski, 2008
USA CL  5  (detail)  328
(-)
IV--501
(-)
-Negative
Tallerico, 1999
USA, Canada CL  1  (detail)  50
(-)
IIIR--51
(-)
-Negative
Verga, 1997
Italy CL  1  (detail)  103
(41%)
IIIR22.8 + 7.1
(-)
37.9 + 10.5
(-)
97
(51%)
53.2 + 16.4
(-)
Negative
Virgos, 2001
Spain PO  1  (detail)  262
(40%)
9-61.4
(19-90)
278
(39%)
54.2
(21-90)
Positive
 Asian
Arinami, 1994
Overlaps with
Arinami, 1996
CL  1  (detail)  156
(37%)
IIIR-48.1
(17-75)
300
(-)
45.2
(31-60)
n.a.
Arinami, 1996
Overlaps with
Itokawa, 1993
CL  1  (detail)  291
(-)
M--579
(-)
-Trend
Arinami, 1997
Japan CL  2  (detail)  260
(46%)
IIIR22.4
(12-39)
44.4
(19-81)
312
(45%)
48.7
(29-75)
Positive
Chen, 1996
Taiwan CL  1  (detail)  114
(50%)
IIIR-40
(-)
88
(60%)
27.5
(-)
Negative
Fan, 2009
China CL  3  (detail)  421
(-)
IV-30.7 + 10.7
(15-70)
404
(-)
28.1 + 8.1
(16-60)
Positive
Fujiwara, 1997
Japan CL  1  (detail)  52
(-)
M--26
(-)
-Negative
Harano, 1997
Japan CL  1  (detail)  70
(34%)
IIIR-47 + 10
(-)
101
(54%)
67 + 15
(-)
Negative
Hattori, 1994
Japan CL  1  (detail)  100
(50%)
IIIR--100
(50%)
-Negative
Himei, 2002
Japan CL  2  (detail)  190
(37%)
IV-53.1 + 11.5
(-)
103
(49%)
33.1 + 10.8
(-)
Negative
Hokyo, 2010
Japan CL  2  (detail)  407
(42%)
IV-54.7
(-)
384
(64%)
40.1
(-)
Negative
Hori, 2001
Japan CL  2  (detail)  241
(49%)
IV-52.7 + 11.5
(-)
201
(50%)
54.7 + 6.8
(-)
Negative
Inada, 1999
Japan CL  1  (detail)  234
(-)
IIIR--94
(-)
-Positive
Itokawa, 1993
Japan CL  1  (detail)  50
(42%)
IIIR--110
(-)
-Negative
Kaneshima, 1997
Japan CL  1  (detail)  78
(55%)
IV-36.3 + 10.1
(19-68)
112
(68%)
23 + 2.1
(18-30)
Negative
Luu, 2008
Taiwan CL  1  (detail)  211
(47%)
IV-43
(-)
201
(55%)
42
(-)
Negative
Morimoto, 2002
Japan CL  1  (detail)  48
(-)
III--48
(-)
-Negative
Nanko, 1994
Overlaps with
Hattori, 1994
CL  1  (detail)  100
(50%)
IIIR--100
(50%)
-n.a.
Ohara, 1996
Japan CL  1  (detail)  153
(50%)
IV26.3 + 9.5
(-)
46.3 + 16
(-)
121
(58%)
34.4 + 14.1
(-)
Negative
Ohara, 1998
Japan CL  1  (detail)  170
(48%)
IV26 + 9.7
(-)
43.5 + 16.1
(-)
121
(58%)
35.4 + 14.2
(-)
Positive
Tanaka, 1996
Japan CL  1  (detail)  106
(48%)
IIIR-44.7 + 11.8
(15-70)
106
(41%)
45.8 + 25
(22-86)
Negative
 Other/Mixed
Behravan, 2008
Iran CL  2  (detail)  38
(55%)
IV-42 + 12
(-)
63
(62%)
46 + 18
(-)
Negative
Cordeiro, 2009
Brazil CL  1  (detail)  229
(35%)
IV-27.2 + 7.5
(19-64)
733
(32%)
31.8 + 9.1
(18-79)
Positive
Gejman, 1994
USA CL  1  (detail)  106
(-)
M--125
(-)
-Negative
Gupta, 2009
India CL  8  (detail)  254
(39%)
IV-29.2 + 7.6
(-)
225
(38%)
31 + 11
(-)
Positive
Kukreti, 2006
Overlaps with
Gupta (2009)
CL  2  (detail)  101
(45%)
IV25.3 + 7.3
(-)
-145
(-)
-n.a.
Pal, 1995
India CL  1  (detail)  156
(37%)
IIIR--300
(-)
-Positive
Srivastava, 2010
India CL  5  (detail)  215
(48%)
IV21.4 + 6.1
(-)
29.3 + 8.9
(-)
215
(40%)
34.6 + 12.4
(-)
Positive
Vijayan, 2007
India CL  5  (detail)  213
(62%)
IV24.4 + 8
(-)
34.4 + 10.8
(-)
196
(-)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Ambrosio, 2004
Portugal  1  (detail)  9090
(36%)
IV--180
(50%)
-Negative
Dubertret, 2001
Overlaps with
Dubertret, 2010 (CC)
 2  (detail)  5050
(26%)
IV--100
(50%)
-n.a.
Dubertret, 2004
Overlaps with
Dubertret, 2010 (CC)
 4  (detail)  103103
(21%)
IV20.7 + 8
(-)
-206
(50%)
-n.a.
Dubertret, 2010
Overlaps with
Dubertret, 2010 (CC)
 4  (detail)  108108
(20%)
IV----Positive
Fallin, 2005
USA  5  (detail)  263274
(26%)
IV19.5 + 4.5
(-)
-548
(50%)
-Negative
Laurent, 1994
France  1  (detail)  51-IIIR----Negative
Schindler, 2002
Portugal  1  (detail)  7878
(38%)
IV--156
(50%)
-Positive
Talkowski, 2008
USA  5  (detail)  150150
(50%)
IV--300
(50%)
-Negative
 Asian
Glatt, 2008
Taiwan  24  (detail)  6161214
(-)
IV--1194
(-)
-Positive
Li, 1998
China  1  (detail)  229229
(37%)
M-29.4 + 10.9
(15-65)
458
(50%)
-Negative
 Other/Mixed
Fanous, 2004
USA  1  (detail)   544
(-)
IIIR--730
(-)
-Negative
Goldman, 1997
USA  1  (detail)   5
(20%)
IIIR--455
(-)
-Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright